BPC-157, or pentadecapeptide BPC, is a game-changer in healing and peptide therapy
Discard compromised vials rather than risk injecting damaged peptide
Cagrilintide has been studied in combination with semaglutide as a fixed-dose therapy, with promising results: the combination amplified weight loss compared to semaglutide alone, while preserving lean mass better than monotherapy
IL-6 impairs insulin action by inhibiting expression of insulin receptor, insulin receptor substrate-1 (IRS-1), and GLUT4 in human preadipocytes as well as 3T3-L1 adipocytes [45, 71]
Compact volumes: mixing to ~2,500 mcg/mL keeps each injection at ~10 units when dosing 250 mcg twice daily
Cells lose efficiency faster